
Sign up to save your podcasts
Or
Jonathan Violin, CEO of Crescent Biopharma and Venture Partner at Fairmount, speaks with Venrock partner Nimish Shah about how the company is keeping a frenetic and exciting pace to generate a new class of drugs while preparing to launch on the public markets later this year.
4.8
6262 ratings
Jonathan Violin, CEO of Crescent Biopharma and Venture Partner at Fairmount, speaks with Venrock partner Nimish Shah about how the company is keeping a frenetic and exciting pace to generate a new class of drugs while preparing to launch on the public markets later this year.
1,271 Listeners
2,185 Listeners
1,014 Listeners
988 Listeners
1,774 Listeners
2,289 Listeners
3,981 Listeners
123 Listeners
317 Listeners
5,916 Listeners
1,544 Listeners
31 Listeners
146 Listeners
11 Listeners
45 Listeners